Denied TMS Appeals

Repetitive transcranial magnetic stimulation for treatment-resistant depression, billed with initial-treatment, delivery and management codes over a course of sessions.

What the independent reviewers decided

69%

overturned by the independent reviewer

of 120 decisions in the corpus

Source

California DMHC independent medical review determinations, 2017-2026. Public record.

Read this as a base rate, not as your odds

These are decisions about other patients, in one state, that had already been through the plan's own internal appeal and were then sent to an outside reviewer. That population is self-selected toward disputes worth pursuing, so the rate says what happened to cases like this at that stage — not what will happen to a specific claim. It is not medical or legal advice.

Why plans deny transcranial magnetic stimulation

The policy requires a specified number of failed antidepressant trials at adequate dose and duration, and the record does not evidence each one.
A required trial of psychotherapy is not documented.
The requested protocol or number of sessions exceeds the policy's allowance.
Re-treatment is denied because the response to the prior course is not documented.

What actually carried the cases that won

Guideline support led here, which is unusual — in most procedures the patient's own history did the deciding. It reflects how these policies are written: they encode a treatment-resistance definition drawn from published criteria, and the overturned records met that definition on its own terms and said which criteria they were meeting. Peer-reviewed literature and FDA labelling were the two authorities reviewers relied on.

What the record showed	Share of overturned decisions
A published guideline supported the request	55%
Conservative treatment was documented as failed	51%
The severity or urgency was documented	41%
Prior treatment was documented	33%
The condition was documented as chronic or long-standing	27%
The diagnosis was confirmed	19%
The functional impact on the patient was documented	14%
Objective findings were documented	4%

Shares are of the overturned decisions and do not sum to 100% — a single decision often rested on more than one, and some rested on none of these.

What the reviewers cited

Peer-reviewed literature — in 63% of the overturned decisions
FDA labeling — in 30% of the overturned decisions
Clinical guidelines — in 22% of the overturned decisions
Standard of care — in 4% of the overturned decisions

transcranial magnetic stimulation denials — frequently asked

Is a denied TMS claim worth appealing?

69% of 120 California independent medical reviews were overturned — better than two in three.

How should failed medication trials be documented?

As trials, not as a list. Agent, dose, duration and outcome for each, because the policy's threshold is defined in those terms. A medication list does not establish adequacy of dose or duration.

Does the device or protocol matter?

Where the policy names accepted protocols, a request outside them needs its own justification. Since FDA labelling was among the authorities reviewers used most in this group, locating the protocol inside a cleared indication is the natural argument.

Source

California Department of Managed Health Care — independent medical review determinations

Denial reasons and criteria are described in plain language for reference and vary by plan and policy. This page reports what independent reviewers decided in a public California dataset; it is general information, not medical, legal, or coverage advice.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →